top of page
Decisions that stand up to scrutiny
Technology commercialisation fails when science, market, IP, regulation, capital and team are
addressed in the wrong order.
I identify the binding constraint and determine what to continue, change, fund or stop.
In 2–3 weeks, you receive an independent written recommendation with the evidence and reasoning required to defend the decision.
Selected institutional & ecosystem work
The outcome is determined between the components.
These factors are usually assessed separately, although their dependencies determine whether progress compounds or stalls. A strong individual component can still be neutralised by the sequence, timing or demands of the others.
I examine where these factors reinforce, constrain or cancel each other out, which one is limiting progress, and in what sequence and proportion they should be addressed. The result is a decision architecture for the strongest defensible path to commercial success.
QUATISE® is the proprietary research and methodology basis behind each engagement. You receive independent judgement – as a decision-ready written record, or as a framework to implement.
What has become too expensive to leave unresolved?
Institutions & Ecosystem
Your next mandate, funding period or board review is approaching. You can show activity – but not yet which interventions are changing outcomes.
I INVESTIGATE How programme design, venture selection, incentives, support and founder behaviour connect to the outcomes being claimed.
YOU CAN DECIDE What to renew, redesign, scale or stop – and the evidence required to defend that decision.
The portfolio keeps consuming capital, but it is difficult to distinguish temporary friction from ventures whose route to market is structurally blocked.
I INVESTIGATE How technical readiness, market demand, regulation, adoption, capital requirements, team capacity and timing constrain one another.
YOU CAN DECIDE Which ventures merit more time and capital, which need a different route to market, and which should be stopped before further investment.
You want the strongest ventures, but credible business builders bypass the programme – or take the funding without valuing the support. Competing offers look largely interchangeable.
I INVESTIGATE How the proposition, selection model, incentives, expertise, funding and assumed scaling route influence who joins and what the programme actually changes.
YOU CAN DECIDE A differentiated offer that stronger ventures choose for reasons beyond free support or grant access.
The evaluation is complete and the recommendation is on paper. But implementation stalls between organisations, decision owners and reporting cycles.
I INVESTIGATE Which dependencies, decision rights, evidence gates and responsibilities must align for the recommendation to work in practice.
YOU CAN DECIDE A sequence that existing teams can implement: who decides what, what happens next and what must become true before further commitment.
Scaleups & Corporates
Customers are interested and pilots are running – but pilots are not becoming repeatable revenue.
I INVESTIGATE How customer urgency, procurement, integration, pricing, regulation, delivery capacity and financing affect the route from interest to adoption.
YOU CAN DECIDE What is preventing conversion, which evidence customers still need and whether the commercial model can scale.
Every expert is convincing within their own domain – technology, IP, regulation, sales, partnerships or finance – but their recommendations do not add up to one executable strategy.
I INVESTIGATE The conflicts and dependencies between those recommendations, tested against the venture’s actual route to adoption and value.
YOU CAN DECIDE One decision logic: what matters now, what can wait and which action unlocks the next commercially relevant proof.
Another grant, programme, pilot, partnership or fundraising round could buy crucial resources – but it is unclear where to invest now for it to eventually pay off.
I INVESTIGATE How each option affects commercial proof, capital requirements, control, timing and future constraints – not merely the next milestone.
YOU CAN DECIDE The next move most likely to change the trajectory, plus the evidence needed before committing scarce time and capital.
Several routes to market look plausible, but technology, customer adoption, IP, regulation, team and capital cannot all advance at once. Which path should receive scarce resources first?
I INVESTIGATE How technical maturity, market demand, IP position, regulatory pathways, adoption requirements, team capacity and funding interact across viable market routes – and which dependency must be resolved first.
YOU CAN DECIDE Which market and route to pursue first, what to prove in what order, and where to commit, defer or stop scarce people and capital.
Independent expertise.
A clear point of view.
I’m Maria, an independent expert connecting science, commercial strategy and capital. Through Arise Innovations®, I help institutions and ventures turn complex evidence into decisions they can act on.
250+ cases assessed · 25+ programmes & ecosystems
€100M+ allocation exposure
My QUATISE® methodology is formally recognised as applied RD&I under OECD Frascati criteria.
bottom of page